YTTRIGA

This brand name is authorized in Austria, Estonia, Spain, France, Ireland, Lithuania, Poland, Romania

Active ingredients

The drug YTTRIGA contains one active pharmaceutical ingredient (API):

1 Yttrium ⁹⁰Y chloride UNII 1K8M7UR6O1 - YTTRIUM Y-90

Yttrium (90Y) chloride is produced by decay of its radioactive precursor Strontium (90Sr). It decays by emission of beta radiation of 2.281 MeV (99.98 %) of maximal energy to stable zirconium (90Zr). 90Y-yttrium has a half-life of 2.67 days (64.1 hours). Read about Yttrium ⁹⁰Y chloride

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
YTTRIGA Radiopharmaceutical precursor, solution	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V10X	Other therapeutic radiopharmaceuticals	V Various → V10 Therapeutic radiopharmaceuticals
Discover more medicines within V10X

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1225707
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 05322001, 05322002
Country: FR	Base de données publique des médicaments	Identifier(s): 61931910
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1029596, 1064335
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100313470
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W52769001